Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.
Since the early 1960s, surgical myotomy-myectomy has been the standard treatment for patients with drug-refractory symptoms due to hypertrophic cardiomyopathy and dynamic outflow tract obstruction. Comparable morphologic and functional results can be achieved by percutaneous septal ablation (PTSMA) by alcohol-induced septal branch occlusion. The circumscribed therapeutic myocardial infarction results in widening of the left ventricular outflow tract with consecutive gradient reduction. Follow-up studies show clinical and objective improvement as well as further gradient reduction due to left ventricular remodeling. In this article, an updated review of the latest results of PTSMA is provided.
Seggewiss
H
H
Medizinische Klinik I, Leopoldina-Krankenhaus, Gustav-Adolf-Strasse 8, 97422, Schweinfurt, Germany. hseggewiss@leopoldina.de
D002312:Cardiomyopathy, Hypertrophic / Q000628:therapy*; D000431:Ethanol / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans
D000431:Ethanol